Auxilium Pharma profit beats estimates as sales of urology drugs rise


Nov 6 (Reuters) - Auxilium Pharmaceuticals Inc reported a better-than-expected adjusted quarterly profit due tohigh sales of its urology drugs and raised the lower end of itsfull-year revenue forecast.

The company said it now expected full-year revenue of $370million to $401 million. It had earlier estimated $363 millionto $405 million.

Auxilium's net loss widened to $28.9 million, or 59 centsper share, in the third quarter ended Sept. 30 from $10.5million, or 21 cents per share, a year earlier.

Excluding items, the company earned 17 cents per share.

Analysts on average had expected 15 cents, according toThomson Reuters I/B/E/S.

View Comments (0)